Session "Health"

Hubert Misslisch, Hannele Lahtinen (moderator)

Christiane Wehle, Sirpa Nuotio (rapporteur)

15.05.2019

Partnership analyses in relation to the cluster 'Health' under Pillar II "Global Challenges and Industrial Competitiveness" of Horizon Europe (Commission proposal):

The intervention areas of the cluster 'Health':

— Health throughout the Life Course

— Environmental and Social Health Determinants

— Non-Communicable and Rare Diseases

— Infectious Diseases

— Tools, Technologies and Digital Solutions for Health and Care

— Health Care Systems

The cluster includes 22 fully relevant partnerships and 6 other fully relevant networks and governance structures:

— 20 P2Ps (4 JPI, 2 EJP, 12 ERA-NET Cofunds, 2 Art 185 initiative)

— 2 PPPs (Art 187)

— 1 EIP

— 1 FET Flagship

— 4 ERICs

Discussion paper - Assigning current partnerships to the intervention areas of the Health cluster

Nr. and Type of Fully Relevant Networks per Intervention Area

Legend: ERIC, EIP, ETP/ETIP, ERA-NET Cofund, JPI, EJP, FET, cPPP, EIT, A185, A187

Main observations

— All types of existing partnerships can be assigned to the (Horizon Europe) Health cluster.

— The majority of these initiatives are P2Ps (n = 20 / 28).

— The most populated intervention area is 'Non-communicable and rare diseases' (n = 15).

Discussion paper - Connections between partnerships and networks in the cluster 'Health'

Formal connection: ──────

e.g. JPI JPND, AMR, HDHL and their Cofunds

Existing collaboration: ══════

e.g. JPND and NEURON (specification of call topics)

Main observations

— The level of connectivity between the various networks and partnerships shows potential for improvement.

— P2Ps have interactions mainly to other health P2Ps.

— There are hardly any interactions between P2Ps, PPP and other networks.

HEALTH

P2P

PPP

JPI
AMR
HDHL
JPND
MYBL

Art 185
AAL2
EDCTP2
EMPIR

ERA-NET Cofund
JPI-EC-AMR
ERA-HDHL
HDHL-INTIMIC
JPco-fuND
JPco-fuND2
ERA-PerMed
ERAcoSysMed
ERA-CVD
E-Rare-3
EuroNanoMed III
NEURON Cofund
TRANSCAN-2
FLAG-ERA

EJP
EJP HBM4EU
EJP One Health
EJP Rare diseases

EIT-KIC
Health

EIP
Active & Healthy Aging

FET Flagship
Human Brain Project

ERIC
BBMRI-ERIC
EATRIS-ERIC
ECRIN-ERIC
INSTRUCT ERIC
SHARE-ERIC

cPPP
Robotics

Art 187
ECSEL
EuroHPC JU
IMI 2

ETP
Nanomedicine

ERA LEARN

Discussion papers - lead questions

Feedback to discussion paper

— Are there any important aspects missing in the report?

— What have been the main strengths and achievements of the existing partnership landscape?

— What have been the main challenges?

Past and current experiences

— What kind of interactions did/do you have with other (P2P, PPP) networks, and which are these networks?

— How did/does this contribute to achieving your partnership's objectives and/or improve performance?

— How can your partnership contribute to increase coherence in the partnership landscape?

Ideas for future developments

— What are the challenges of the new partnership proposal?

— How could the cooperation between different types of partnerships be improved to support the reformation of the partnership landscape?

— Which actions need to be taken? By whom?

Preliminary list of candidates for European Partnerships in Pillar II, III and cross-pillar, and short description of what the partnership stands and aims for		Currently envisaged implementation mode(s)	Predecessors	Composition of partners	Relevance for clusters/ pillars
Health	**1. EU-Africa Global Health Partnership** Increase health security in sub-Saharan Africa and Europe, by accelerating the clinical development of effective, safe, accessible, suitable and affordable health technologies as well as health systems interventions for infectious diseases in partnership with Africa and international funders.	Article 185 or Article 187 or Co-programmed or co-funded	EDCTP2 (Art.185)	MS/AC and 3rd countries (i.e. sub-Saharan African countries) Foundations/industry on an ad-hoc basis	Cl.1
	2. Innovative Health Initiative A collaborative platform bringing the pharmaceuticals, diagnostics, medical devices, imaging and digital sectors together for precompetitive R&I in areas of unmet public health need, to accelerate the development and uptake of people-centred health care innovations.	Article 187 or Co-programmed	IMI2 (Art.187)	Industry, other organisations on an ad hoc basis	Cl.1
	3. European partnership for chemicals risk assessment Bring together the European risk assessment and regulatory agencies to implement a joint research agenda, to ensure their capacity to deal with persistent or emerging challenges. It will promote the uptake of new methods, tools, technologies and information in chemical hazard identification and risk assessment and as part of this, sustain the development and use of human biomonitoring capacities in Europe.	Co-funded	Human Bio-monitoring and a number of other actions	MS/AC, National agencies, tbd the role of the corresponding EU agencies	Cl.1, 4, 6
	4. Pre-clinical/clinical health research The partnerships aims for establishing and implementing a strategic research agenda and joint funding strategy between major European public funders in health research.	Co-funded	Around 10 previous and current ERA-NET actions	MS / AC / 3rd countries	Cl.1, 6
	5. Large-scale innovation and transformation of health systems in a digital and ageing society Improving health and care models in an ageing, data-driven and digital society, shifting to holistic health promotion and person-centred care approaches through health policy and health systems research.	Co-funded	AAL2 (Art.185), JPI 'More Years, Better Lives' and others	MS / AC Civil Society organisations	Cl.1
	6. Personalised Medicine To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine and enhance the European collaboration with non-EU countries	Co-funded	ERA-PerMed and actions in support of ICPerMed	MS / AC	Cl.1
	7. Rare Diseases To improve the integration, the effectiveness, the production and the social impact of research on rare diseases through the development, demonstration and promotion of Europe/ world-wide production, sharing and exploitation of research and clinical data, materials, processes, knowledge and know-hows.	Co-funded	EJP Rare diseases (until 2023)	MS/AC /3rd countries, civil society organisations, EU research infrastructures	Cl.1

Participants, partnerships, Horizon Europe candidate list

first name	last name	organisation	country	partnership	candidate list #
Klaus	Niederlander	AAL Association	Belgium	Article 185 AAL Programme	5
Iris	Ontavilla	IMI	Belgium	Article 187 Innovative Medicines Initiative (IMI)	2
Magali	Poinot	IMI	Belgium	Article 187 Innovative Medicines Initiative (IMI)	2
Sören	Haar	EIT Health	Belgium	EIT Health	40
Philipp	Weise	UBA	Germanny	EJP HBM4EU	3
Daria	Julkowska	INSERM - EJP RD	France	EJP on Rare Diseases	7
Marc	Kirschner	PT Jülich	Germany	ERA-Net Cofund ERAcoSysMed; CSA EU-STANDS4PM	4?
Maria	Romero	Italian Ministry of Health	Italy	ERA-Net Cofund TRANSCAN-2	4?
Erica	Hackenitz	ZonMw	The Netherlands	ERA-Net Cofund TRANSCAN-2, CSA TO-REACH (health systems)	4? 5
Sabine	Bradler	PT Jülich	Germany	FET Flagship Human Brain Project	n.a.
Denise	Moi Thuk Shung	ZonMw	Netherlands	JPI More Years, Better Lives	5
Lianne	van Horen	ZonMw	The Netherlands	JPI More Years, Better Lives	5
Laura	Plant	JPIAMR	Sweden	JPIAMR	4?
Philippe	Amouyel	Univ Lille / Inserm	France	JPND	4?
Abida	Durrani	ZonMW	The Netherlands	JPND	4?
Delphine	Smagghe	Inserm Transfert	France	JPND	4?
Hannele	Lahtinen	Academy of Finland	Finland	ERA-Net Cofund NEURON, ERA-LEARN	4?
Sirpa	Nuotio	Academy of Finland	Finland	ERA-Net Cofund NEURON, ERA-LEARN	4?
Astrid	Flandorfer	FFG	Austria	ERA-LEARN	
Christiane	Wehle	DLR	Germany	ERA-LEARN	
Hubert	Misslisch	DLR	Germany	Health-related P2Ps with BMBF/DLR-PT involvement	1, 4?, 6, 7